{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:23:59Z","timestamp":1784622239711,"version":"3.55.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of rituximab (RTX) to those of intravenous cyclophosphamide (IVCY) as remission induction therapy in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and severe renal impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the REVEAL cohort, this retrospective multicentre study enrolled 96 newly diagnosed patients with AAV and an estimated glomerular filtration rate of &amp;lt;\u200930\u00a0ml\/min\/1.73\u00a0m2. The patients were divided into RTX and IVCY groups. Matching weights were used to adjust for baseline characteristics. The primary outcome was a 2-year composite of all-cause mortality or end-stage kidney disease (ESKD). Secondary outcomes included all-cause mortality, ESKD, relapse, and hospitalisation-requiring infections. Outcomes were assessed using multivariable Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the weighted population, the hazard ratio for RTX versus IVCY was 0.73 (95% confidence interval: 0.31\u20131.72) for the primary composite outcome, with no significant intergroup difference. Similarly, intergroup differences in the hazard ratios for all-cause mortality, ESKD, relapses, and hospitalisation-requiring infections were not significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RTX and IVCY demonstrated comparable efficacy in preventing mortality and ESKD in this high-risk population. RTX is a viable option for patients with AAV and severe renal impairment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf124","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:11:35Z","timestamp":1765458695000},"page":"610-618","source":"Crossref","is-referenced-by-count":2,"title":["Rituximab\n                    <i>versus<\/i>\n                    intravenous cyclophosphamide for anti-neutrophil cytoplasmic antibody-associated vasculitis with severe renal impairment: A multicentre REVEAL cohort study"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5655-6356","authenticated-orcid":false,"given":"Hirofumi","family":"Miyake","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital , Nara ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayana","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2190-0780","authenticated-orcid":false,"given":"Takuya","family":"Kotani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneyuki","family":"Hatta","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Shiomi","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1089-5296","authenticated-orcid":false,"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-060X","authenticated-orcid":false,"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-7644","authenticated-orcid":false,"given":"Hideki","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kobe City Medical Center General Hospital , Hyogo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4980-2664","authenticated-orcid":false,"given":"Shuji","family":"Sumitomo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kobe City Medical Center General Hospital , Hyogo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaho","family":"Jo","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, Yodogawa Christian Hospital , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Fujiki","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, Yodogawa Christian Hospital , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Health Information Management, Kurashiki Sweet Hospital , Okayama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikihito","family":"Shoji","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Manabe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6968-5712","authenticated-orcid":false,"given":"Ryosuke","family":"Hiwa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"2026070605220904400_ref1","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1093\/rheumatology\/keaf240","article-title":"British Society for Rheumatology Guideline Steering Group. The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis","volume":"64","author":"Biddle","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026070605220904400_ref2","doi-asserted-by":"crossref","first-page":"103139","DOI":"10.1016\/j.autrev.2022.103139","article-title":"Histopathological prognostic factors in ANCA-associated glomerulonephritis","volume":"21","author":"Boud'hors","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2026070605220904400_ref3","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/ndt\/gfae035","article-title":"A predictive mortality score in ANCA-associated renal vasculitis","volume":"39","author":"Fage","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026070605220904400_ref4","doi-asserted-by":"crossref","first-page":"6369814","DOI":"10.1155\/2018\/6369814","article-title":"Prognostic factors for survival and relapse in ANCA-associated Vasculitis with renal involvement: a clinical long-term follow-up study","volume":"2018","author":"Salmela","year":"2018","journal-title":"Int J Nephrol"},{"key":"2026070605220904400_ref5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2026070605220904400_ref6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026070605220904400_ref7","first-page":"1777","volume-title":"Ovarian Reserve Diminished by Oral Cyclophosphamide Therapy for Granulomatosis with Polyangiitis (Wegener's)","author":"Clowse","year":"2011"},{"key":"2026070605220904400_ref8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/rheumatology\/keu372","article-title":"Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis","volume":"54","author":"Faurschou","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2026070605220904400_ref9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2026070605220904400_ref10","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. KDIGO 2024","year":"2024","journal-title":"Kidney Int"},{"key":"2026070605220904400_ref11","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1681\/ASN.2019111197","article-title":"Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated Vasculitis with severe kidney disease","volume":"31","author":"Casal Moura","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026070605220904400_ref12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026070605220904400_ref13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","article-title":"DCVAS INVESTIGATORS. 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis","volume":"81","author":"Suppiah","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026070605220904400_ref14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2021-221795","article-title":"DCVAS Investigators. 2022American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis","volume":"81","author":"Robson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026070605220904400_ref15","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026070605220904400_ref16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40620-015-0208-y","article-title":"Rituximab for treatment of severe renal disease in ANCA associated vasculitis","volume":"29","author":"Geetha","year":"2016","journal-title":"J Nephrol"},{"key":"2026070605220904400_ref17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.2006.062711","article-title":"EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"66","author":"Hellmich","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2026070605220904400_ref18","first-page":"30","article-title":"Multiple imputation with multivariate imputation by chained equation (MICE) package","volume":"4","author":"Zhang","year":"2016","journal-title":"Ann Transl Med"},{"key":"2026070605220904400_ref19","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s10238-022-00915-z","article-title":"Predictors of poor prognosis in ANCA-associated vasculitis (AAV): a single-center prospective study of inpatients in China","volume":"23","author":"Gao","year":"2023","journal-title":"Clin Exp Med"},{"key":"2026070605220904400_ref20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.46497\/ArchRheumatol.2021.8687","article-title":"Predictors of renal and patient outcomes in anti-neutrophil cytoplasmic antibody-associated vasculitis: our single-center, tertiary care experience","volume":"36","author":"Toraman","year":"2021","journal-title":"Arch Rheumatol"},{"key":"2026070605220904400_ref21","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.23912","article-title":"Spanish Registry of Systemic Vasculitis, the Autoimmune Systemic Diseases Study Group, and the Spanish Society of Internal Medicine. Comparison of the Birmingham vasculitis activity score and the five-factor score to assess survival in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 550 patients from Spain (REVAS Registry)","volume":"72","author":"Solans-Laqu\u00e9","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2026070605220904400_ref22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10067-022-06419-1","article-title":"Analysis of the risk factors for end-stage renal disease and mortality in ANCA-associated vasculitis: a study from a single center of the Chinese rheumatism data center","volume":"42","author":"Guo","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2026070605220904400_ref23","first-page":"S5","article-title":"Clinical analysis of ANCA-associated renal vasculitis patients with chronic dialysis","volume":"32","author":"Chen","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2026070605220904400_ref24","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/aje\/kwk052","article-title":"Relaxing the rule of ten events per variable in logistic and Cox regression","volume":"165","author":"Vittinghoff","year":"2007","journal-title":"Am J Epidemiol"},{"key":"2026070605220904400_ref25","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1093\/rheumatology\/keae219","article-title":"Effectiveness of intravenous methylprednisolone pulse in patients with severe microscopic polyangiitis and granulomatosis with polyangiitis","volume":"63","author":"Omura","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026070605220904400_ref26","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/mr\/roaf053","article-title":"Safety of glucocorticoid dose reduction in microscopic polyangiitis: a multicentre REVEAL cohort study","volume":"35","author":"Miyake","year":"2025","journal-title":"Mod Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf124\/65854322\/roaf124.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/610\/65854322\/roaf124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/610\/65854322\/roaf124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:22:26Z","timestamp":1783329746000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/4\/610\/8377966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,12]]},"published-print":{"date-parts":[[2026,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf124","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2025,12,12]]}}}